AAIPharma Expands Laboratory Service Offerings and Capabilities in its Technology Center

WILMINGTON, N.C. AAIPharma Services Corp. (“AAIPharma”), a leading provider of pharmaceutical product development services, announced today the expansion of laboratory service offerings, capabilities and instrumentation in its state-of-the-art laboratory Technology Center in Wilmington, N.C. 

Following the company’s opening of its Technology Center in May, 2012, AAIPharma has continued investing in its service offerings and acquired additional instrumentation to support its analytical and biopharmaceutical development laboratories.

“AAIPharma specializes in comprehensive service offerings and offers the latest in instrumentation for our clients,” said Patrick Walsh, chief executive officer of AAIPharma.  “Since its grand opening, the Technology Center has been recognized for its modern, efficient operations and has exceeded client expectations as a world class laboratory.”

AAIPharma continues to focus on serving clients’ needs and has added new ICP-MS, GC-MS, LC-MS, UPLC and HPLC systems to its expansive list of instrumentation and capabilities to meet growing market demands.  A Malvern™ Mastersizer 3000 particle size analyzer was added to support preformulation and material testing services.

The company expanded its biopharmaceutical development services by adding a ProteinSimple MFI™5200 micro-flow imaging system, a Wyatt Dawn® Heleos®II multi-angle laser light scattering (MALS) detector and a Wyatt DynaPro NanoStar dynamic light scattering (DLS) detector to support aggregate and particulate testing services.  A ProteinSimple iCE3 capillary IEF was added to further support protein analyses.

AAIPharma also expanded its extractable and leachable (E&L) testing services to evaluate and qualify the materials used in the manufacturing process and final product configuration.  AAIPharma’s subject matter experts already provide exceptional E&L testing services, and new capabilities include a Foss Soxtec™ 2050 automated extraction system to enable reproducible and robust methodologies.

About AAIPharma Services Corp. 

AAIPharma Services Corp. is a leading provider of contract services that support all phases of drug development. The company’s wide array of capabilities includes analytical chemistry, formulation development, material testing services, microbiology, clinical and commercial contract manufacturing, pharmaceutical packaging, and stability services. Serving more than 600 clients around the globe and headquartered in Wilmington, N.C., AAIPharma is a portfolio company of Water Street Healthcare Partners, a strategic private equity firm focused exclusively on health care.

For more information on the company, visit www.aaipharma.com.

 

Related Links:

AAIPharma’s Analytical Development Capabilities
http://aaipharma.com/development/analytical-development

AAIPharma’s Biotechnology, Biopharmaceutical and Structural Chemistry Capabilities
http://aaipharma.com/development/analytical-chemistry/biotechnology-services

AAIPharma News and Events:
http://aaipharma.com/news-and-events/

AAIPharma Home Page:
http://aaipharma.com

 

Media Contact:

Jeff A. Parrott, Ph.D.
media_relations@aaipharma.com